A detailed history of Van Eck Associates Corp transactions in Novo Nordisk A S stock. As of the latest transaction made, Van Eck Associates Corp holds 492,467 shares of NVO stock, worth $41.9 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
492,467
Previous 427,832 15.11%
Holding current value
$41.9 Million
Previous $61.1 Million 6.67%
% of portfolio
0.07%
Previous 0.09%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

BUY
$119.07 - $145.42 $7.7 Million - $9.4 Million
64,635 Added 15.11%
492,467 $57 Million
Q2 2024

Jul 31, 2024

BUY
$122.71 - $146.91 $2.45 Million - $2.93 Million
19,931 Added 4.89%
427,832 $61.1 Million
Q1 2024

Apr 30, 2024

BUY
$102.11 - $135.92 $8.49 Million - $11.3 Million
83,164 Added 25.61%
407,901 $52.4 Million
Q4 2023

Feb 05, 2024

BUY
$87.78 - $105.45 $4.52 Million - $5.43 Million
51,451 Added 18.83%
324,737 $33.6 Million
Q3 2023

Nov 08, 2023

BUY
$90.94 - $199.54 $14 Million - $30.7 Million
153,755 Added 128.63%
273,286 $24.9 Million
Q2 2023

Aug 03, 2023

SELL
$155.98 - $172.65 $3.8 Million - $4.2 Million
-24,333 Reduced 16.91%
119,531 $19.3 Million
Q1 2023

May 03, 2023

SELL
$132.34 - $159.14 $11.8 Million - $14.1 Million
-88,798 Reduced 38.17%
143,864 $22.9 Million
Q4 2022

Feb 08, 2023

SELL
$102.55 - $135.33 $3.08 Million - $4.06 Million
-30,027 Reduced 11.43%
232,662 $31.5 Million
Q3 2022

Oct 27, 2022

BUY
$95.28 - $116.93 $396,269 - $486,311
4,159 Added 1.61%
262,689 $26.2 Million
Q2 2022

Aug 03, 2022

BUY
$103.24 - $121.81 $9.04 Million - $10.7 Million
87,543 Added 51.2%
258,530 $28.8 Million
Q1 2022

May 10, 2022

BUY
$93.1 - $112.54 $1.38 Million - $1.67 Million
14,839 Added 9.5%
170,987 $19 Million
Q4 2021

Jan 26, 2022

SELL
$95.88 - $117.08 $852,181 - $1.04 Million
-8,888 Reduced 5.39%
156,148 $17.5 Million
Q3 2021

Nov 03, 2021

BUY
$84.42 - $106.62 $1.99 Million - $2.51 Million
23,516 Added 16.62%
165,036 $15.8 Million
Q2 2021

Aug 10, 2021

SELL
$67.66 - $84.76 $1.35 Million - $1.7 Million
-20,001 Reduced 12.38%
141,520 $11.9 Million
Q1 2021

May 13, 2021

SELL
$67.06 - $75.82 $1.19 Million - $1.35 Million
-17,755 Reduced 9.9%
161,521 $10.9 Million
Q4 2020

Feb 09, 2021

BUY
$63.89 - $73.8 $129,888 - $150,035
2,033 Added 1.15%
179,276 $12.5 Million
Q3 2020

Nov 12, 2020

BUY
$63.69 - $70.22 $1.13 Million - $1.25 Million
17,732 Added 11.12%
177,243 $12.3 Million
Q2 2020

Aug 10, 2020

SELL
$58.54 - $67.94 $67,906 - $78,810
-1,160 Reduced 0.72%
159,511 $10.4 Million
Q1 2020

May 12, 2020

SELL
$49.46 - $64.78 $648,618 - $849,524
-13,114 Reduced 7.55%
160,671 $9.67 Million
Q4 2019

Feb 13, 2020

BUY
$49.86 - $58.26 $1.59 Million - $1.86 Million
31,952 Added 22.53%
173,785 $10.1 Million
Q3 2019

Nov 08, 2019

SELL
$47.54 - $53.43 $1.04 Million - $1.17 Million
-21,909 Reduced 13.38%
141,833 $7.33 Million
Q2 2019

Aug 07, 2019

SELL
$46.79 - $52.47 $1.2 Million - $1.35 Million
-25,665 Reduced 13.55%
163,742 $8.36 Million
Q1 2019

May 13, 2019

SELL
$46.36 - $52.63 $3.78 Million - $4.29 Million
-81,509 Reduced 30.09%
189,407 $9.91 Million
Q4 2018

Feb 12, 2019

SELL
$41.54 - $47.25 $183,149 - $208,325
-4,409 Reduced 1.6%
270,916 $12.5 Million
Q3 2018

Nov 13, 2018

SELL
$46.76 - $51.24 $1.06 Million - $1.16 Million
-22,729 Reduced 7.63%
275,325 $13 Million
Q2 2018

Aug 13, 2018

BUY
$44.29 - $50.42 $2.25 Million - $2.56 Million
50,777 Added 20.53%
298,054 $13.7 Million
Q1 2018

May 11, 2018

SELL
$48.49 - $58.14 $532,662 - $638,667
-10,985 Reduced 4.25%
247,277 $12.2 Million
Q4 2017

Feb 12, 2018

SELL
$47.53 - $53.73 $1.37 Million - $1.55 Million
-28,911 Reduced 10.07%
258,262 $13.9 Million
Q3 2017

Nov 09, 2017

SELL
$41.15 - $49.22 $1.39 Million - $1.66 Million
-33,722 Reduced 10.51%
287,173 $13.8 Million
Q2 2017

Aug 11, 2017

BUY
N/A
320,895
320,895 $13.8 Million

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $192B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Van Eck Associates Corp Portfolio

Follow Van Eck Associates Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

News

Stay updated on Van Eck Associates Corp with notifications on news.